

# Discovery of first-in-Class AMD treatment for dry eye using Autophagy activation

Vasthera Co., Ltd



OPHTHALMOLOGY	Lead
Product Type	Chemical product
Indication	Dry Age-Related Macular Degeneration (Dry-AMD)
Target	Autophagy signal pathway
MoA(Mechanism of Action)	Regulation of selective autophagy signaling in retinal pigment epithelium
Competitiveness	Lineage cell therapeutics: OpRegen (Retinal pigmented epithelial cell therapy) Phase II. Genentech Inc. : RG6147(galegenimab) Phase II. Alexion Pharmaceuticals(Danicopan, small molecule) Phase II Ionis pharmaceuticals (Licensed out to Roche) : IONIS-FB-LRX Phase II. Apellis pharma. : Pegcetacoplan (C3 inhibitor, peptide/SC). Marketed.
Development Stage	Lead
Route of Administration	Oral administration